Cargando…
Japan’s Drug Regulation Framework: Aiming for Better Health or Bigger Profits?
Autores principales: | Ozaki, Akihiko, Senoo, Yuki, Saito, Hiroaki, Crump, Andy, Tanimoto, Tetsuya |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Kerman University of Medical Sciences
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7947705/ https://www.ncbi.nlm.nih.gov/pubmed/32610799 http://dx.doi.org/10.34172/ijhpm.2020.56 |
Ejemplares similares
-
Bigger is bigger. Better is better
por: Solheim, Ole, et al.
Publicado: (2011) -
Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan
por: Hashimoto, Takanao, et al.
Publicado: (2022) -
Negative Aspects of the Regional Quota System in Japan
por: Yamamoto, Kana, et al.
Publicado: (2019) -
Are the issues pointed out by ChatGPT can be applied to Japan? - Examining the reasons behind high COVID-19 excess deaths in Japan
por: Kaneda, Yudai, et al.
Publicado: (2023) -
Underperformance of Reverse-Transcriptase Polymerase Chain Reaction in Japan and Potential Implications From Diamond Princess Cruise Ship and Other Countries During the Ongoing COVID-19 Pandemic
por: Yamamoto, Kana, et al.
Publicado: (2020)